Skip to main content
SpringerLink
Log in
Book cover

Glaukom und Makula 2010 pp 143–154Cite as

Pegaptanib zur Behandlung des diabetischen Makulaödems

Ergebnisse der Phase-III-Studie – Zellbiologische und physiologische Aspekte der Anti-VEGF-Behandlung

  • Chapter

  • 945 Accesses

Zusammenfassung

Eine Erkrankung der Makula ist in den Industrienationen der häufigste Grund für eine Erblindung. Nach WHO-Daten von 2002 sind die Ursachen hierfür in den Industrienationen zu 50% auf die altersabhängige Makuladegeneration (AMD) und zu ca. 18% auf die diabetische Retinopathie zurückzuführen (Resnikoff et al. 2004). Große Hoffnung für die Behandlung der exsudativen Form der AMD brachte die Einführung einer lokalen Therapie am Auge, die den »vascular endothelial growth factor« (VEGF) hemmt. Der Wachstumsfaktor VEGF spielt sowohl bei der AMD als auch bei der diabetischen Retinopathie eine entscheidende Rolle bei der Entstehung und Progression. Inhibitoren von VEGF sind zugelassene Medikamente für die Behandlung der altersabhängigen Makuladegeneration seit 2004. Die erste Zulassung erhielt Pegaptanib (Macugen®, Fa. Pfizer) und kurz darauf Ranibizumab (Lucentis®, Fa. Novartis). Zusätzlich zu den zugelassenen Präparaten findet sich eine breite Anwendung von Bevacizumab (Avastin®, Fa. Roche Pharma AG), ebenfalls ein VEGF-Inhibitor, der für die Behandlung bei Darmkrebs entwickelt wurde und nur hierfür zugelassen ist.

This is a preview of subscription content, log in via an institution.

eBook
USD   9.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   19.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM (2010) Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 117: 946–953

    Article  PubMed  Google Scholar 

  • Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGFreceptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457–10461

    Article  PubMed  CAS  Google Scholar 

  • Browning AC, Dua HS, Amoaku WM (2008) The effect of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells. Br J Ophthalmol 92: 1003–1008

    Article  PubMed  CAS  Google Scholar 

  • Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, Soares R (2009) Coparative effects of bevacizumab, ranibizumab, pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 88: 522–527

    Article  PubMed  CAS  Google Scholar 

  • Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, Vasques L, Soares R (2009) Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem 108: 1410–1417

    Article  PubMed  CAS  Google Scholar 

  • Cunningham ET Jr, Adamis AP, Altaweel M et al.; Macugen Diabetic Retinopathy Study Group (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747–1757

    Article  PubMed  Google Scholar 

  • Diabetic Retinopathy Clinical Research Network (2008) Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115: 1447–1459

    Article  Google Scholar 

  • Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796–1806

    Google Scholar 

  • Erickson KK, Sundstrom JM, Antonetti DA (2007) Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 10: 103–117

    Article  PubMed  Google Scholar 

  • Friburg TR, Tolentino M, LEVEL Study Group, Weber P, Patel S, Campbell S, Goldbaum M (2010) Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 94: 1611–1617

    Article  Google Scholar 

  • Furguson TA, Apte RS (2008) Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol 30: 111–119

    Article  Google Scholar 

  • Gandreault J, Fei D, Rusit J, Suboc P, Shin V (2005) Preclinical pharmacokinetics of Ranibizumab (Ahu Fab V2) after a single intravitreal administration. Invest. Ophthalmol Vis Sci 46: 726–733

    Article  Google Scholar 

  • Heiduschka P, Fietz H, Hofmeister S et al.; The Tübingen Bevacizumab Study Group (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814–2823

    Article  PubMed  Google Scholar 

  • Hussain N, Ghanekar Y, Kaur J (2007) The future implications of anti-vascular endothelial growth factor therapy in ophthalmic practise. Indian J Ophthalmol 55: 445–450

    Article  PubMed  Google Scholar 

  • Inan ÜÜ, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773–1781

    Article  PubMed  Google Scholar 

  • Joussen AM, Smyth N, Niessen C (2007) Pathophysiology of diabetic macular edema. Dev Ophthalmol 39: 1–12

    Article  PubMed  CAS  Google Scholar 

  • Klettner A, Roider J (2008) Comparison if Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49: 4523–4527

    Article  PubMed  Google Scholar 

  • Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167: 1451–1459

    Article  PubMed  CAS  Google Scholar 

  • Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-months randomized controlled double-masked multicenter phase II study. Diabetes Care 33: 2399–2405

    Article  PubMed  CAS  Google Scholar 

  • Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

    Google Scholar 

  • Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248: 915–930

    Article  PubMed  CAS  Google Scholar 

  • Nishijima K, Ng YS, Zhong L et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. AJP 171: 53–67

    PubMed  CAS  Google Scholar 

  • Peters S, Heiduschka P, Julien S, Ziemssen, F, Fietz H, Bartz-Schmidt KU, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995–1002

    Article  PubMed  CAS  Google Scholar 

  • Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844–851

    PubMed  Google Scholar 

  • Schmidt-Erfurth U (2010) Clinical safety of renibizumab in age-related macular degeneration. Expert Opin Drug Saf Evaluation 9: 149–165

    Article  CAS  Google Scholar 

  • Simó R, Carrasco E, García-Ramírez M, Hernández C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71–98

    Article  PubMed  Google Scholar 

  • Spitzer MS, Yoeruck E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt K, Szurman P (2007) Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells, Graefes Arch Clin Exp. Ophthalmol 245: 1937–1842

    Google Scholar 

  • Stefánsson E (2001) The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 79: 435–440

    Article  PubMed  Google Scholar 

  • Sugimato H, Hamamo Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605–12608

    Article  Google Scholar 

  • Wang X, Wang G, Wang Y (2009) Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 148: 883–889

    Article  PubMed  CAS  Google Scholar 

  • Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanizied anti-VEGF antibody in vitro. Angiogenesis 7: 223–345

    Article  Google Scholar 

  • Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES) (2008) Twelf-month safety of intravitreal injections of bevazizumab (Avastin); results of the Pan American Collaborative Retina Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81–87

    Article  PubMed  CAS  Google Scholar 

  • Ziemssen F, Zhu Q, Peters S, Grisanti S, ELW ar dani M, Szurman P. Bartz-Schmidt KU, Tuebingen Bevacizumab Studygroup, Ziemssen T (2008) Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 29: 213–224

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Augenheilkunde, Klinikum Chemnitz gGmbH, Flemmingstr. 2, 09116, Chemnitz

    Prof. Dr. med. Katrin Engelmann & Dr. med. Klio Ai Becker

Authors
  1. Prof. Dr. med. Katrin Engelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Klio Ai Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Engelmann, K., Becker, K.A. (2011). Pegaptanib zur Behandlung des diabetischen Makulaödems. In: Glaukom und Makula 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-22054-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-22054-8_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-22053-1

  • Online ISBN: 978-3-642-22054-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation